Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.
Corash
L
L
Cerus Corporation, Concord, LA 94520, USA. larrycorash@ceruscorp.com
D016913:Blood Component Transfusion / Q000379:methods / Q000592:standards; D001803:Blood Transfusion / Q000592:standards*; D003140:Communicable Disease Control / Q000379:methods* / Q000592:standards; D006801:Humans; D007937:Leukapheresis / Q000592:standards*; D007962:Leukocytes / Q000382:microbiology* / Q000469:parasitology / Q000821:virology